Funding Opportunities

Our partners' latest funding opportunities are advertised below – the most recent opportunity is at the top of the list. Please scroll down for further opportunities and note that deadlines are included in the text of the post. Click on the links in the funding announcement section at the right to find general information about funding schemes offered by each of our partner organizations.

Latest Announcements
Topic Funding Announcements
Normal topic
Test 2




Normal topic
Test 2

New Test 2



Normal topic

Testing the image upload on funding organizationImage to testing purposes

Normal topic
World Cancer Research Fund International - Regular Grant Programme 2021/2022

World Cancer Research Fund International (WCRF International) is now accepting grant applications for research on the links between diet, nutrition (including body composition) and physical activity and cancer, as part of its Regular Grant Programme 2021/2022 cycle.

Eligibility: Applicants can be based in any country outside the Americas. More information on the eligibility and the scientific scope of the grant call is available from (Applications from the Americas can be submitted to the American Institute for Cancer Research at Applications from an eligible principal investigator with co-applicants/collaborators from anywhere in the world are welcome.

Please ensure you read the ‘Guidelines for research grant applicants & award recipients’ carefully before applying.

The deadline for applications is 16th November 2021.


Normal topic
NCI - Notice of Intent to Publish: Funding Opportunity Announcement for Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)

Please share within your networks. The estimated publication date of the funding opportunity announcement is August 5, 2021.

The National Cancer Institute (NCI) plans to publish a Funding Opportunity Announcement (FOA) as an RFA (i.e., Request for Applications) for the "Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs)” Initiative (U01).This FOA aims to support implementation science to accelerate the integration of evidence-based cancer control interventions for PLWH into HIV treatment and prevention programs worldwide by leveraging existing infrastructure. The FOA solicits applications in implementation science to address gaps in the delivery of evidence-based cancer control among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control strategies for PLWH worldwide. This Notice of Intent to Publish (NOITP) encourages multi-disciplinary teams of researchers with expertise in HIV or cancer and in implementation science to consider developing responsive applications that address the cancer control needs of PLWH populations in LMIC settings. 

Normal topic
Request for Application - Pancreatic and biliary tract cancers (Trials) - Deadline LOI 30 June 2021

The Anticancer Fund and the Rising Tide Foundation for Clinical Cancer Research are pleased to announce a joint Request for Application (RFA) about pancreatic and biliary tract cancers.

We are seeking to support clinical trials testing novel and unique strategies in the treatment of patients diagnosed with pancreatic ductal adenocarcinomas (PDAC) and/or biliary tract cancer (BTC). The proposal needs to have the potential to have a high impact (e.g. improve cure rate or survival) on the treatment of these cancers.

We foresee a total budget of 3 million US dollars and we anticipate supporting up to 1-3 trials with this budget.

All details of this opportunity are available here:

Thanks in advance for spreading the news!


Normal topic
Grant Round Open! Worldwide Cancer Research 2021 Grant Round

About Worldwide Cancer Research

We are a UK based charity funding early stage, discovery research anywhere in the world.

We have a history of recognising innovative scientific ideas that have the chance to revolutionise cancer medicine. We were founded 40 years ago to support brand new avenues of research and allow scientists to take intellectual risks in exploring challenging new concepts and approaches.

If you have a novel, exciting and creative idea that could help prevent, diagnosis or treat cancer, we may be able to support you with a project grant. Since our foundation in 1979, we have invested in nearly 2,000 research projects around the world.

Many of these projects have already improved the lives of people with cancer, and others are opening entirely new areas of cancer research. However, we know there is still so much to do, and this is where you come in.

What do we fund?

We award project grants of up to £250,000 and of 12 to 36 months in length to support basic, fundamental or translational research into the prevention, diagnosis or treatment of cancer. More information about what we fund and what we are looking for in a project can be found in our Research Strategy.

How to apply

Our 2021 grant round opens on Monday 15th February. Submission period for applications opens on Thursday 4th March and submission closes on Friday 2 April. Please visit our website for more information or contact the Research Funding team at


Normal topic
NCI - Funding Opportunity Announcement (FOA): Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

NCI is pleased to announce the publication of a new NCI funding opportunity announcement (FOA): Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional).

NCI will host an informational webinar for potential applicants on Friday, March 12th from 9:00 AM to 10:30 AM Eastern Time. NCI program staff will present on the scope and focus of the program and take questions from interested potential applicants.

Open Date: May 02, 2021

Expiration Date: June 03, 2021

This new FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria.

This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Visit the ACTs webpage at for additional program contacts, answers to frequently asked questions, and information on previously funded ACTs awards.

Normal topic
NCI - Administrative Supplement Opportunity to study the impact of COVID-19 on global cancer prevention and control

The NCI is pleased to announce the Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control (NOT-CA-21-033).

The purpose of this NOSI is to inform current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes. 

CGH will be hosting a webinar to address frequently asked questions about this funding opportunity on Thursday, February 25, 2021 at 9:00 a.m. EST.  Click here to join the webinar, or copy and paste the following link into your browser We encourage you to share this information widely among your networks. If you have any questions about this NOSI, or the upcoming FAQ webinar, please do not hesitate to contact Elise Garton and Paul Pearlman.

Deadline: 31 March 2021

Eligibility and Eligible Individuals (Program Director/Principal Investigator):

To be eligible for an Urgent Competitive Revision or an Administrative Supplement through this NOSI and the respective FOA, applications must meet the following criteria:

  • Administrative supplement applications are limited to currently funded projects supported by NCI.
  • PDs/PIs must hold an active award eligible for PA-20-272 supported through NCI with sufficient time (minimum 1 year) left to complete the studies proposed after the revision/supplement has been awarded within the existing project period.
  • The proposed project for supplemental funding is required to be within the scope of the parent award and be a logical extension of the original aims.
  • The parent award must either already include a foreign performance site in an LMIC or the applicant must include a letter of support from an LMIC institution with the application.
  • For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.
Normal topic
AIRC Start Up Grant for young investigators

The AIRC Start-Up grant program is for talented young scientists with a strong commitment to cancer research, seeking the opportunity of becoming independent investigators and setting up their own lab in Italy after a successful research experience abroad.

The grant amount is up to 1 million euro in 5 years.

• must not have been back in Italy for more than 12 months by the deadline;
• must have at least 2 first/co-first, last/co-last, corresponding/co-corresponding primary research paper in the last 5 years;

Applicants should be 35 years old or younger by the time of the submission application’s deadline. Some degree of flexibility to this age-limit is applied (provided that applicants meet the other eligibility criteria), but in case of equal merit preference will be given to younger candidates.

The 2021 call is now open, click here to find out more (deadline March 5). Don’t miss this opportunity to establish a new independent laboratory in Italy!

Normal topic
Oncology Nursing Foundation - Nurse scientist focused grant opportunities

Applications are now open for the following funding schemes:

Addressing Cancer Health Disparities Through Evidence-Based Cancer Nursing Research (RE42) $100,000 - deadline May 17, 2021

  • Purpose: To support oncology nursing research addressing cancer health disparities, including in the topic areas of breast, colorectal, lung or prostate cancer.

Addressing the Adverse Effects of Immunotherapy and Emerging Therapies on Cancer Patients (RE43) $150,000 - deadline May 17, 2021

  • Purpose: To support oncology nursing research in symptom science addressing the adverse effects of immunotherapy and emerging therapies used in the treatment of cancer patients. Symptom Science in immunotherapy and emerging therapies has been identified as one of the top cancer nursing research priorities in need of new knowledge

Eligibility: The principal investigator must be a registered nurse actively involved in some aspect of cancer patient care, education or research and be PhD or DNSc prepared that has received and completed at least one research study of at least $50,000 as PI. Membership in ONS is not required. Open to international applicants.

For full details, visit:

Normal topic
General Research Grant- Open Topic in Cancer Nursing Science (RE02)

The Oncology Nursing Foundation is pleased to announce that the General Research Grant is now open. For further information please visit the ONF website

  • Letters of Intent (RE02) Due: April 15, 2021 (Separate Application)
  • LOI acceptance notifications: May 3rd, 2021
  • Upon LOI acceptance, Research Grant Application Due: June 8th, 2021
  • Funding Level: $50,000 over 2 years
  • Funding Available: August/September 2021

Purpose of Grant: To support rigorous scientific oncology nursing research. Research projects may include investigator-initiated research, pilot or feasibility studies, supplements to current funded projects, or developing a new aspect of a program of research. Funding preference is given to projects that involve nurses in the design and conduct of the research activity and that promote theoretically based oncology practice. Competitive applications will addresses the ONS Research Agenda See "Research Agenda of the Oncology Nursing Society: 2019-2022," published in the Oncology Nursing Forum, November 2019, Volume 46, No. 6.
The following three (3) key areas in need of oncology nursing research articulated in the ONS Research Agenda are:
     • Symptom Science in Immunotherapy and Emerging Therapies in Precision Health and Biosignatures
     • Health Disparities
     • Palliative and Psychosocial Oncology Care

Eligibility:  The principal investigator (individual primarily responsible for implementing the proposal and reporting to Oncology Nursing Foundation) must be a registered nurse actively involved in some aspect of cancer patient care, education, or research and be PhD or DNSc prepared (only one PI can appear on the grant). The application is open to international applicants.

Normal topic
Request for Application - Evolutionary Therapy (Trials) - Deadline LOI 1 March 2021

Opportunity open to applicants from all countries. Please read the eligibility criteria & instructions carefully before applying: 

This Request for Application (RFA) seeks to increase clinical trial activity of evolutionarily informed therapeutic strategies aiming at improving survival outcomes of cancer patients.

Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker.

This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria).

We encourage investigators working on evolutionarily informed strategies (including adaptive therapy) to apply for funding for their clinical trial evaluating such approach in cancer patients.

For further information on what is seen as evolutionarily informed strategies and adaptive therapy, we would like to refer applicants to a recent article by Gatenby & Brown (Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 2020; 17: 675–86).

Please contact for any questions related to the RFA and to check eligibility of their proposal in case of doubt.

Normal topic
American Society for Radiation Oncology call for grant and fellowship applications

The American Society for Radiation Oncology (ASTRO) is accepting applications from U.S. based early career scientists for the 2021 Grants and Fellowships Program. ASTRO is offering residents/fellows seed grants and career development awards to support novel research projects and foster the intellectual research talent currently entering the field of radiation oncology. ASTRO has also partnered with companies to offer ASTRO - Industry Radiation Oncology Research Training Fellowships that provide unique research training opportunities for U.S. based residents to work directly in the industry setting for up to one year. Please visit for more information. To apply and find the detailed Program Announcements please visit ProposalCentral.

Eligibility: U.S. based early career scientists

The fellowships deadline is January 8, 2021 and grants deadline is February 26, 2021

For questions please email

Normal topic
Cancer Grand Challenge: deadline 22 April 2021

Cancer Research UK and the US National Cancer Institute have united to define a new era in cancer research and discovery:

Cancer Grand Challenges: Dare to take on some of the most complex challenges in cancer   

Cancer Grand Challenges is a global funding platform founded by Cancer Research UK and the National Cancer Institute. Through a series of £20m ($25m) awards, Cancer Grand Challenges is giving international teams of researchers the freedom to think differently, act creatively and explore truly innovative science to take on complex questions in cancer. 

Nine new challenges to the international research community are now open for applications.
Call closes: 22 April 2021  

Cancer Grand Challenges news and updates – follow the team on Twitter and LinkedIn



Normal topic
World Cancer Research Fund International call for grant applications

World Cancer Research Fund International (WCRF International) is now accepting grant applications for research on the links between diet, nutrition (including body composition) and physical activity and cancer, as part of its Regular Grant Programme 2020/2021 cycle.

Please pass this information on to colleagues who might be interested in applying. Visit for more information.

Applications are accepted from principal investigators based at institutions in any country outside the Americas (North America, Central America and the Caribbean, and South America). Applications from the Americas can be submitted to the American Institute for Cancer Research at Applications from an eligible principal investigator with co-applicants/collaborators from anywhere in the world are welcome.

Only applications that meet the eligibility criteria and adhere to WCRF's research principles and themes will be considered. Please note the grant programme’s scope has been updated: applicants are encouraged to read the application guidelines carefully before applying
(link to guidelines PDF:

The deadline for applications is 16th November 2020.

Any questions can be emailed to, but please refer to the FAQs and guidelines document in the first instance.

Normal topic
Funding new arms of multi-arm trials for rare cancers

We, the Anticancer Fund, a Belgian non-profit organization with an international scope, have joined forces with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss-based non-profit organization, for a unique opportunity to support high quality clinical trials focusing on drug repurposing and therapy optimization, with special interest in the following areas:

  • Rare cancers (<6/100,000)
  • ‘Financial orphan’ drugs (commercially neglected drugs)
  • Off patent drugs
  • Prognostic and/or predictive biomarkers

We call upon all investigators to submit proposals, where funding is required to initiate a new arm of an existing multi-arm trial. Requirements include having a strong rationale with rigorous and compelling supportive data, in addition to a detailed statistical design and methodology.

Amount available for this call for proposals will be at least US$ 3 million. The amount allocated per grant will depend on the number of proposals selected for funding. Application Deadline is February 28, 2020

All information can be found here:

Please share this information with anyone potentially interested and/or retweet to spread the news:

Normal topic
Request for Applications - Trials in curative setting - International - Deadline 16 June 2019

We are seeking to support clinical trials aiming at reducing recurrence rates for cancer patients treated with curative intent.
The focus is on cancer types (or well-defined sub-types), with high rates of recurrence despite curative-intent treatments.

The funding can go to
- A new trial
- A new arm in an existing multi-arm trial
- Participation of an additional country in an existing international trial
- Extra-funding for an under-funded existing trial

You will find all details and eligibility criteria here:

Feel free to retweet the following tweet to inform your network about this opportunity:

Funding Announcements & Feeds


Links to pages giving general funding announcements for researchers are included below, where available. Organizations are listed alphabetically. Where an organization has a specific focus that is not evident from the name, this is noted in brackets after the name. Organizations marked (CC) have a specific focus on childhood cancer. If you have any questions, please contact us.








South Africa